GIVLAARI (GIVOSIRAN) RECEIVES FDA APPROVAL!!
The American Porphyria Foundation is pleased to announce that the Food and Drug Administration has granted APPROVAL for GIVLAARI (Givosiran) for the treatment of Acute Hepatic Porphyria!
US patients will now have access to this preventative RNAi treatment. This approval is the first step in gaining access to GIVLAARI (Givosiran) in the US. Availability to patients will progress as Alnylam Pharmaceuticals pivots from FDA approval to commercial availability.
The APF will update you frequently on progress related to access and distribution of GIVLAARI (Givosiran) treatment.
Congratulations to YOU, our patient community, who participated in the pivotal Phase 2 and Phase 3 clinical trials that led to this approval. You are our medical heroes!
REMEMBER…RESEARCH IS THE KEY TO YOUR CURE!
Click Here to See the Full FDA Press Release
FDA grants approval to Givlaari (givosiran) for the treatment of adult patients with acute hepatic porphyria